secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001023024-25-000072
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharma posts preliminary Q2 ILUVIEN/YUTIQ revenue of $22.3M; NEW DAY trial misses primary endpoint
--------------------------------------------------------------------------------

- Preliminary combined ILUVIEN/YUTIQ net revenues for Q2 2025: $22.3M.
- NEW DAY trial primary endpoint: mean supplemental injections 2.4 (ILUVIEN) vs. 2.5 (aflibercept); p=0.756, not significant.
- Secondary endpoint met: mean time to first supplemental injection 185.4 vs. 132.8 days (p<0.001).
- Post-hoc per-protocol analysis: ILUVIEN arm 1.8 vs. 2.5 supplemental injections (p=0.029); total 2.8 vs. 7.5 injections.
- Safety: 41% treatment-related TEAE in ILUVIEN arm (cataract, IOP increase) vs. 3% in aflibercept arm.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000072/0001023024-25-000072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302425000072/ani-20250723.htm
  HTML page:      https://secwatch.observer/filing/0001023024-25-000072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer